Exicure Reaches Nasdaq Compliance Milestone After Filing Delay Resolved

Exicure, Inc. (Nasdaq: XCUR) Successfully Restores Compliance with Nasdaq Filing Standards REDWOOD CITY, Calif.—(BUSINESS WIRE)—Exicure, Inc., a biotechnology firm in the clinical development stage specializing in therapies for blood-related diseases, announced today that as of July 1, 2025, it has reestablished its compliance with Nasdaq's periodic filing obligations under Listing Rule 5250(c)(1). This achievement follows the submission of its quarterly reports on Form 10-Q to the U.S. Securities and Exchange Commission for the quarter ending March 31, 2025. Nasdaq's Listing Qualifications Department confirmed that the company is now in good standing and has addressed the previous deficiency. About Exicure Exicure, Inc. has traditionally focused on creating nucleic acid-based treatments that target RNA molecules associated with validated disease pathways. After recent restructuring efforts and a pause in clinical development, the company is now evaluating strategic options to enhance shareholder value, leveraging both its existing biotechnology assets and broader initiatives. Additional information is available at www.exicuretx.com. Media Contact: Sarah Ellinwood, PhD Kendall I...